Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study

Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors (ICIs) is needed. We retrospectively collected baseline clinicopathological characteristics i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The oncologist (Dayton, Ohio) Ohio), 2024-03, Vol.29 (3), p.e372-e381
Hauptverfasser: Pecci, Federica, Cantini, Luca, Cognigni, Valeria, Perrone, Fabiana, Mazzaschi, Giulia, Agostinelli, Veronica, Mentrasti, Giulia, Favari, Elda, Maffezzoli, Michele, Cortellini, Alessio, Rossi, Francesca, Chiariotti, Rebecca, Venanzi, Francesco Maria, Lo Russo, Giuseppe, Galli, Giulia, Proto, Claudia, Ganzinelli, Monica, Tronconi, Francesca, Morgese, Francesca, Campolucci, Carla, Moretti, Marco, Vignini, Arianna, Tiseo, Marcello, Minari, Roberta, Rocchi, Marco Luigi Bruno, Buti, Sebastiano, Berardi, Rossana
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors (ICIs) is needed. We retrospectively collected baseline clinicopathological characteristics including circulating lipid profile (total cholesterol [TC], triglycerides [TG], low-density lipoproteins [LDL], high-density lipoproteins [HDL]) of patients with consecutive solid cancer treated with ICIs, and we investigated their role in predicting clinical outcomes. At a median follow-up of 32.9 months, among 430 enrolled patients, those with TC ≥ 200 mg/dl showed longer median progression-free survival (mPFS; 6.6 vs. 4.7 months, P = .4), although not reaching statistical significance, and significantly longer median overall survival (mOS; 19.4 vs. 10.8 months, P = .02) compared to those with TC 
ISSN:1083-7159
1549-490X
DOI:10.1093/oncolo/oyad273